Saudi Arabia Over the past three years, Sanofi has significantly expanded its presence in the GCC region, launching 40-50 new products, including treatments for rare diseases and advancements in immunology, diabetes management, and vaccines. As Jean-Paul Scheuer explains, this expansion aligns with Sanofi’s goal to become a leading immunology company globally and…
Mexico Four years ago, Daniel Del Conde left a career in multinational pharma to become the CEO of regional player Grupo Somar. He walks us through the company’s activities – private labels; pure generics; private brand manufacturing, and prescription, its recent acquisition of Quifa, and the diversified portfolio that encompasses over…
Germany A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in the US and Germany; Bayer’s elimination of some 1,500 jobs, and BioNTech’s bid for MediLink’s solid tumour platform. Merck…
Global As Big Pharma makes evermore declarations on its sustainability credentials, who are the industry’s most sustainable companies? With wildlife under severe threat from biopharmaceutical run-off, which companies are truly dedicated to change? Which are truly dedicated to equitable pay structures and promoting diversity, equity and inclusion? To answer these questions,…
Saudi Arabia Fadi Ghanayem, Managing Director for Saudi Arabia and Caucasus, Central Asia, Iran and Mongolia (CCAIM) at French diagnostics firm BioMérieux discusses the remarkable growth he has witnessed in Saudi Arabia thanks to the government’s push to improve healthcare and prevention in recent years. In addition, he outlines the opportunities that…
Saudi Arabia Prof. Ayman Abdo, SVP of Saudi private healthcare cornerstone Fakeeh Care Group, outlines the group’s large range of activities, encompassing a network of hospitals, home care services, ambulance systems, and an IT company, as well as its own medical, nursing and pharmacy schools. He shares his current focus on Public-Private…
USA A public health initiative said to have saved over 25 million lives, the US President’s Emergency Plan for AIDS Relief (PEPFAR) has had an enormous impact on the fight against HIV/AIDS through providing HIV treatment, prevention, and education. Since its inception in 2003 PEPFAR has largely enjoyed bipartisan support within…
Global One of the doyens of European biotech is stepping back from general management. Jean-Paul Clozel founded rare disease focused Actelion along with his wife Martine Clozel in 1997, a company that went on to become publicly traded and launch three blockbuster drugs. The Clozels then sold up to J&J for…
Global Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access to HIV treatment and prevention. Iyer highlights the impact of voluntary licensing of drugs via the Medicines Patent Pool and…
Saudi Arabia Abdul Latif Jameel is one of Saudi Arabia’s most storied distributors, with a history dating back to 1945. Although present in the healthcare space since 1995 via its philanthropic activities, it has only recently moved to set up a dedicated healthcare arm, known as Jameel Health. Led by Big Pharma…
China After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune disease R&D, now has an extensive pipeline, with a BTK inhibitor for hematological cancers holding particular potential. In conversation with…
UAE Long-established as the Middle East and Africa’s leading country in terms of rapid access to biomedical innovation, the UAE is looking to bolster this positioning in the coming years. Indeed, allowing innovation to flourish – including through hosting greater numbers of clinical trials in the country and protecting intellectual property…
See our Cookie Privacy Policy Here